found that the combination of pembrolizumab and nCRT as treatment for gastroesophageal junction adenocarcinoma achieved an improved pCR rate in patients with Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥ 10 compared with those with PD-L1 CPS < 10 (50% vs. 13.6%, p = 0.046) (18). This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.